Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

Breast |  Leukemia |  Lung |  Lymphoma |  Myelomas |  Pancreatic |  Prostate |  Renal |  Solid Tumors |







  • Capecitabine +/- Ruxolitinib for Metastatic Pancreatic Cancer
    A randomized, double-blind, phase 3 study of the JAK1/2 inhibitor, Ruxolitinib or Placebo in combination with Capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas who have failed or are intolerant to first-line chemotherapy



  • MPDL3280A in Advanced Renal Cell Cancer
    A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated Advanced Renal Cell Carcinoma

Solid Tumors

  • MEDI4736 (anti-PDL-1) in Solid Tumors
    A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors. This trial is currently open to the following disease types: Squamous Lung and Bladder Cancer.